Blood

Vol. 146, Issue 12 Issue 12 2025
19
Articles

Articles in this Issue

Azacitidine as therapy for VEXAS syndrome

David P. Steensma, Mrinal M. Patnaik Sep 18, 2025 pp. 1380-1382 10.1182/blood.2025029732

Immunochemotherapy for older patients with ATLL: a new option?

Ambroise Marcais Sep 18, 2025 pp. 1379-1380 10.1182/blood.2025029797

Introduction to a review series on the structural underpinnings of hemostatic plugs and thrombotic occlusions

Thomas L. Ortel Sep 18, 2025 pp. 1377-1378 10.1182/blood.2025030314

Structure and function are the 2 critical knowledge elements that must be combined for complex systems such as occlusive thrombus formation to be understood. Edited by Associate Editor Thomas L. Ortel...

All in one place: the future of blood group typing

Aline Floch, Thierry Peyrard Sep 18, 2025 pp. 1387-1388 10.1182/blood.2025030071

Array genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participants

Nicholas S. Gleadall, Lianne Koets, Olga Shamardina et al. Sep 18, 2025 pp. 1511-1524 10.1182/blood.2025028902

Abstract Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against nonself antigens remains a significant problem, particularly in patients...

Dangerous clones with complex ties to AL amyloidosis

Giovanni Palladini, Stefan Schönland Sep 18, 2025 pp. 1384-1385 10.1182/blood.2025029888

Structure and interactions of the proteins from the contact system

Jonas Emsley, Yujie Ma, Joost C. M. Meijers Sep 18, 2025 pp. 1422-1430 10.1182/blood.2024025322

Abstract The contact system includes factor XII (FXII), FXI, prekallikrein (PK), and high-molecular-weight kininogen (HK), and has received increased interest as a potential target i...

Structure-based design of therapeutics to control hemostasis

Luke J. Tucker, Krista Hilmas, Ashley C. Brown Sep 18, 2025 pp. 1431-1439 10.1182/blood.2024025323

Abstract Hemorrhage causes millions of deaths and hundreds of billions of dollars in medical costs every year, and a large percentage of trauma bleeding–associated deaths occur in th...

Factor XIII: driving (cross-)links in hemostasis, thrombosis, and disease

James P. Luyendyk, Matthew J. Flick, Alisa S. Wolberg Sep 18, 2025 pp. 1412-1421 10.1182/blood.2024025321

Abstract Blood clots are complex structures composed of blood cells and proteins held together by a structural framework provided by an insoluble fibrin network. Factor (F)XIII is a...

Platelet activation and signaling in thrombus formation

Frauke Swieringa, Johan W. M. Heemskerk, Alice Assinger Sep 18, 2025 pp. 1400-1411 10.1182/blood.2024025320

Abstract In thrombosis and hemostasis, the formation of a platelet-fibrin thrombus or clot is a highly controlled process that varies, depending on the pathological context. Major si...

Loss of DCAF8 impairs hematopoietic stem cell function with cellular senescence via the DOCK11-CDC42 axis

Pengfei Xu, Xiuli Zhang, Donghe Li et al. Sep 18, 2025 pp. 1462-1475 10.1182/blood.2024027335

Abstract Hematopoietic stem cells (HSCs) are responsible for sustaining the hematopoietic system throughout life, and their functional decline contributes to hematological disorders...

UPS delivers apolarity and senescence to HSCs

Hartmut Geiger Sep 18, 2025 pp. 1382-1383 10.1182/blood.2025030420

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

Makoto Yoshimitsu, Ilseung Choi, Shigeru Kusumoto et al. Sep 18, 2025 pp. 1440-1449 10.1182/blood.2024027902

Abstract No standard of care for older patients with aggressive adult T-cell leukemia/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxoru...

Loss of <i>BAP1</i> defines a unique subtype of <i>TP53</i>-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

Jaclyn Andricovich, Coen Johannes Lap, Alexandros Tzatsos Sep 18, 2025 pp. 1493-1510 10.1182/blood.2024026417

Abstract Mutations in TP53 are mutually exclusive with other known drivers of myeloid transformation and define a distinct molecular subtype within de novo acute myeloid leukemia (AM...

Exploring the thrombus niche: lessons learned and potential therapeutic opportunities

John W. Weisel, Rustem I. Litvinov Sep 18, 2025 pp. 1389-1399 10.1182/blood.2024025319

Abstract Thrombus structure and composition are the main determinants of the severity, course, and outcomes of thrombosis. Detailed thrombus morphology has become available due to me...

<i>BAP1/TP53</i> loss defines a BCL-xL–dependent erythroleukemia

Tzu-Chieh Ho, Reuben Kapur Sep 18, 2025 pp. 1385-1387 10.1182/blood.2025030074

Diverse ancestry genotyping of blood cell antigens

Sep 18, 2025 pp. 1525-1525 10.1182/blood.2025031166

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Nicolas A. Gort-Freitas, Maria Moscvin, Matteo C. Da Vià et al. Sep 18, 2025 pp. 1476-1492 10.1182/blood.2024024719

Abstract AL amyloidosis is a disorder characterized by expansion of clonal plasma cells in the bone marrow and distant end organ damage mediated by misfolded immunoglobulin free ligh...

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon et al. Sep 18, 2025 pp. 1450-1461 10.1182/blood.2024028133

Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe monogenic disorder caused by somatic mutations in ubiquitin-like modifier activating en...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page